Cantor Fitzgerald reiterates Summit Therapeutics stock rating

Jefferies upgraded Summit Therapeutics (SMMT) to 'Buy' with a $25.00 price target, up from $15.00. The company has a $13.99B market cap, a GF Score of 30, and significant insider buying. SMMT focuses on novel antibiotics, with ridinilazole targeting Clostridiodes difficile infections. The high P/S ratio suggests overvaluation.

Summit Therapeutics (SMMT) shares rose 5.8% premarket after Jefferies upgraded it to Buy from Hold, raising its price target to $25 from $15. The upgrade anticipates positive progression-free survival data for ivonescimab in 2026, with a potential overall survival benefit in early 2027.

Summit Therapeutics (SMMT) shares rose 5.8% premarket after Jefferies upgraded it to Buy and raised its price target to $25. The upgrade is ahead of expected H3 progression-free survival data in late 2026, with Jefferies predicting statistical significance and a potential overall survival win by early 2027. The analyst cited the company's mechanism of action and ivonescimab's first-in-class status as key drivers.

Summit Therapeutics (SMMT) announced that its partner Akeso reported a statistically significant overall survival benefit for ivonescimab over pembrolizumab in the Phase 3 HARMONi-2 study. The trial involved 398 patients with advanced non-small cell lung cancer. Earlier data showed ivonescimab's median progression-free survival was 11.1 months, compared to 5.8 months for pembrolizumab. The hazard ratio was 0.51, indicating a 49% reduction in progression or death risk. Summit did not disclose the

Summit Therapeutics (SMMT) shares rose 28.19% week-on-week after its partner, Akeso, reported positive Phase 3 trial results for ivonescimab in non-small cell lung cancer, showing improved overall survival over pembrolizumab. Additionally, ivonescimab demonstrated superiority in a biliary tract cancer trial. Final results are pending presentation at medical conferences. Institutional investors reduced holdings despite increased hedge fund interest.

Summit Therapeutics (SMMT) shares rose 19.5% after its partner, Akeso Inc., reported positive Phase III trial results for ivonescimab in biliary tract cancer. The drug showed significant survival and response benefits over a competitor. Summit projects $897.3M revenue and $169.7M earnings by 2029, implying a 66% upside. The FDA decision on ivonescimab's BLA is a key upcoming catalyst.